A Phase 1 interventional study of Aclidinium Bromide 400 μg in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase I, single centre, open-label study to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide in healthy Chinese male and female subjects.
Screening will be performed within 21 days of dosing on Day 1. Eligible participants will be admitted to the trial center on Day -1.
Subjects will receive single dose on Day 1, twice daily regimen is from D5 to D8, and only morning dose will be given on Day 9.
During treatment period, from Day 1 through Day 11 at Visit 2, safety measurements (blood pressure, 12-lead ECG; and AE/SAE monitoring) and blood samples for PK assessments will be collected at predetermined time points.
Clinical laboratory tests (haematology, serum biochemistry and urinalysis) will be performed under fasting conditions at Day -1 at Visit 2.
A follow-up visit will be performed on Day 15.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One inhalation from the 400 μg Aclidinium Bromide inhaler.
Drug: Aclidinium Bromide 400 μg
Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
Maximum Observed Plasma Concentration (Cmax)
Characterization of Cmax, taken directly from the individual concentration-time curve after single dose or multiple dose.
Time frame: Day 1 and Day 9
Time to Reach Maximum Observed Concentration (Tmax)
Characterization of Tmax, taken directly from the individual concentration-time curve after single dose or multiple dose.
Time frame: Day 1 and Day 9
Area Under the Concentration-time From Zero to Infinity (AUCinf)
Characterization of AUCinf (single dose). Area under the concentration time curve from time zero extrapolated to infinity. AUC(0-∞) is estimated by AUC(last) + Clast/λz where Clast is the last observed quantifiable concentration.
Time frame: Day 1
Area Under the Concentration-time From Time 0 to 12 Hours Post-dose [AUC(0-12)]
The AUC(0-12) of aclidinium bromide and its metabolites after single dose of aclidinium bromide in healthy Chinese participants is investigated. Description of the AUC(0-12), partial area under the concentration- time curve in the dose interval after single dose or multiple dose.
Time frame: Day 1 and Day 9
Area Under the Concentration-time From Zero to the Last Quantifiable Concentration (AUClast)
Characterization of AUClast, taken directly from the individual concentration-time curve after single dose or multiple dose.
Time frame: Day 1 and Day 9
Half-life Associated With Terminal Slope of a Semi-logarithmic Concentration-time Curve (t½λz)
Characterization of t½λz, of aclidinium bromide and its metabolites after single and multiple doses of aclidinium bromide in healthy Chinese participants.
Time frame: Day 1 and Day 9
Apparent Total Body Clearance From Plasma After Extravascular Administration (CL/F)
Characterization of CL/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.
Time frame: Day 1 and Day 9
Volume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F)
Characterization of Vz/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.
Time frame: Day 1 and Day 9
Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf)
Characterization of MRTinf, of aclidinium bromide after single dose of aclidinium bromide in healthy Chinese participants.
Time frame: Day 1
Minimum Observed Drug Concentration (Cmin)
Characterization of Cmin, taken directly from the individual concentration-time curve after single dose or multiple dose.
Time frame: Day 1 and Day 9
Average Drug Concentration Over a Dosing Interval (Cavg)
Characterization of Cavg, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants.
Time frame: Day 9
Accumulation Ratio for Cmax [Rac(Cmax)]
Characterization of Rac(Cmax), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmax) is caculated as a ratio for Cmax estimated as (ratio of Css,max on Day 9/Cmax on Day 1).
Time frame: Day 9
Accumulation Ratio for Cmin (Rac[Cmin])
Characterization of Rac(Cmin), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmin) is calculated as ratio for Cmin estimated as (ratio of Css, Cmin on Day 9/ Cmin on Day 1)
Time frame: Day 9
Accumulation Ratio for AUCτ (Rac[AUC])
Characterization of Rac(AUC), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(AUC), calculated as ratio of AUC(0-12) on day 9 and AUC0-12 on Day 1.
Time frame: Day 9
Fluctuation Index During a Dosing Interval (%Fluc)
Characterization of %Fluc, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. The %Fluc index is estimated as 100 x (Cmax- Cmin)/Cav.
Time frame: Day 9
Number of Participants With Adverse Events (AEs)
The safety, and tolerability of aclidinium bromide 400 μg BID after single and multiple dose administration in healthy Chinese participants was evaluated.
Time frame: From Screening (Day -21 to Day -2) until the follow-up visit (Day 15)
The study was conducted at one study centre in China between 14 October 2021 to 26 November 2021.
| Milestone | Aclidinium Bromide 400 μg |
|---|---|
| Started | 43 |
| Completed | 20 |
| Not completed | 23 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Screening failure (non-fulfilment of inclusion/exclusion criteria) | 18 |
Characterization of Cmax, taken directly from the individual concentration-time curve after single dose or multiple dose.
| pg/mL | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 238.6 ± 51.67 | 341.3 ± 40.24 |
| LAS34850 (inactive acid metabolite) | 3831 ± 24.99 | 4891 ± 16.52 |
| LAS34823 (inactive alcohol metabolite) | 164.0 ± 45.05 | 294.1 ± 39.93 |
Characterization of Tmax, taken directly from the individual concentration-time curve after single dose or multiple dose.
| Hour | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 0.08 (0.08 to 0.10) | 0.08 (0.08 to 0.10) |
| LAS34850 (inactive acid metabolite) | 3.00 (2.00 to 3.00) | 2.50 (1.50 to 3.00) |
| LAS34823 (inactive alcohol metabolite) | 0.08 (0.08 to 0.50) | 0.08 (0.08 to 0.50) |
Characterization of AUCinf (single dose). Area under the concentration time curve from time zero extrapolated to infinity. AUC(0-∞) is estimated by AUC(last) + Clast/λz where Clast is the last observed quantifiable concentration.
| h*pg/mL | Single Dose (Day 1) |
|---|---|
| Aclidinium bromide | 266.1 ± 59.15 |
| LAS34850 (inactive acid metabolite) | 29970 ± 17.63 |
| LAS34823 (inactive alcohol metabolite) | 684.4 ± 48.04 |
The AUC(0-12) of aclidinium bromide and its metabolites after single dose of aclidinium bromide in healthy Chinese participants is investigated. Description of the AUC(0-12), partial area under the concentration- time curve in the dose interval after single dose or multiple dose.
| h*pg/mL | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 167.1 ± 40.19 | 357.8 ± 32.28 |
| LAS34850 (inactive acid metabolite) | 22730 ± 18.64 | 33910 ± 15.33 |
| LAS34823 (inactive alcohol metabolite) | 438.1 ± 37.26 | 1031 ± 25.56 |
Characterization of AUClast, taken directly from the individual concentration-time curve after single dose or multiple dose.
| h*pg/mL | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 208.9 ± 57.23 | 609.4 ± 36.49 |
| LAS34850 (inactive acid metabolite) | 29010 ± 18.02 | 50370 ± 16.78 |
| LAS34823 (inactive alcohol metabolite) | 550.4 ± 54.05 | 1849 ± 25.49 |
Characterization of t½λz, of aclidinium bromide and its metabolites after single and multiple doses of aclidinium bromide in healthy Chinese participants.
| Hour | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 13.50 ± 91.55 | 21.42 ± 25.63 |
| LAS34850 (inactive acid metabolite) | 8.322 ± 26.83 | 12.68 ± 18.98 |
| LAS34823 (inactive alcohol metabolite) | 9.964 ± 42.98 | 17.66 ± 12.35 |
Characterization of CL/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.
| Liter/hour | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Apparent Total Body Clearance From Plasma After Extravascular Administration (CL/F) | 1503 ± 59.15 | 1118 ± 32.28 |
Characterization of Vz/F, of aclidinium bromide after single and multiple doses of aclidinium bromide in healthy Chinese participants.
| Liter | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Volume of Distribution (Apparent) Following Extravascular Administration Based on Terminal Phase (Vz/F) | 29280 ± 45.53 | 34550 ± 40.89 |
Characterization of MRTinf, of aclidinium bromide after single dose of aclidinium bromide in healthy Chinese participants.
| Hour | Single Dose (Day 1) |
|---|---|
| Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf) | 13.45 ± 95.18 |
Characterization of Cmin, taken directly from the individual concentration-time curve after single dose or multiple dose.
| pg/mL | Single Dose (Day 1) | Multiple Dose (Day 9) |
|---|---|---|
| Aclidinium bromide | 3.251 ± 56.25 | 11.55 ± 41.22 |
| LAS34850 (inactive acid metabolite) | 647.8 ± 20.84 | 1223 ± 19.34 |
| LAS34823 (inactive alcohol metabolite) | 14.82 ± 31.53 | 43.03 ± 28.55 |
Characterization of Cavg, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants.
| pg/mL | Multiple Dose (Day 9) |
|---|---|
| Aclidinium bromide | 29.82 ± 32.28 |
| LAS34850 (inactive acid metabolite) | 2826 ± 15.33 |
| LAS34823 (inactive alcohol metabolite) | 85.95 ± 25.56 |
Characterization of Rac(Cmax), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmax) is caculated as a ratio for Cmax estimated as (ratio of Css,max on Day 9/Cmax on Day 1).
| Ratio | Aclidinium Bromide 400 μg |
|---|---|
| Aclidinium bromide | 1.431 ± 44.18 |
| LAS34850 (inactive acid metabolite) | 1.277 ± 20.40 |
| LAS34823 (inactive alcohol metabolite) | 1.794 ± 45.61 |
Characterization of Rac(Cmin), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(Cmin) is calculated as ratio for Cmin estimated as (ratio of Css, Cmin on Day 9/ Cmin on Day 1)
| Ratio | Aclidinium Bromide 400 μg |
|---|---|
| Aclidinium bromide | 3.554 ± 50.32 |
| LAS34850 (inactive acid metabolite) | 1.888 ± 22.90 |
| LAS34823 (inactive alcohol metabolite) | 2.903 ± 37.70 |
Characterization of Rac(AUC), of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. Rac(AUC), calculated as ratio of AUC(0-12) on day 9 and AUC0-12 on Day 1.
| Ratio | Aclidinium Bromide 400 μg |
|---|---|
| Aclidinium bromide | 2.141 ± 37.64 |
| LAS34850 (inactive acid metabolite) | 1.492 ± 16.84 |
| LAS34823 (inactive alcohol metabolite) | 2.354 ± 40.94 |
Characterization of %Fluc, of aclidinium bromide and its metabolites after multiple doses of aclidinium bromide in healthy Chinese participants. The %Fluc index is estimated as 100 x (Cmax- Cmin)/Cav.
| Percentage | Multiple Dose (Day 9) |
|---|---|
| Aclidinium bromide | 1102 ± 34.70 |
| LAS34850 (inactive acid metabolite) | 128.9 ± 14.90 |
| LAS34823 (inactive alcohol metabolite) | 289.2 ± 35.31 |
The safety, and tolerability of aclidinium bromide 400 μg BID after single and multiple dose administration in healthy Chinese participants was evaluated.
| Participants | Aclidinium Bromide 400 μg |
|---|---|
| Any AE | 5 |
| Any AE with outcome = death | 0 |
| Any SAE (including events with outcome = death) | 0 |
| Any AE leading to discontinuation of IP | 0 |
| Any AE of special interest | 1 |
Collected over From Screening (Day -21 to Day -2) until the follow-up visit (Day 15). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aclidinium Bromide 400 μg | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Event | Aclidinium Bromide 400 μg |
|---|---|
| SyncopeNervous system disorders | 1/20 |
| Atrial escape rhythmCardiac disorders | 1/20 |
| Orthostatic hypotensionVascular disorders | 1/20 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/20 |
| Mouth ulcerationGastrointestinal disorders | 1/20 |
| Alanine aminotransferase increasedInvestigations | 1/20 |
| Aspartate aminotransferase increasedInvestigations | 1/20 |
The safety analysis set included all participants who received at least 1 dose of IP and for whom any safety post-dose data were available.
| Age, Continuous(years) | Aclidinium Bromide 400 μg |
|---|---|
| Mean | 27.15 ± 5.20 |
| Sex: Female, Male(Participants) | Aclidinium Bromide 400 μg |
|---|---|
| Female | 9 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | Aclidinium Bromide 400 μg |
|---|---|
| Asian/Chinese | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Nov 2021, 1 month.
Results were first posted in Dec 2023, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aclidinium bromide